Login Register Cart 0
Generic placeholder image

Current Radiopharmaceuticals

Editor-in-Chief

ISSN (Print): 1874-4710
ISSN (Online): 1874-4729

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Formulation and In-vivo Characterization of 177Lu-tin-colloid as a Radiosynovectomy Agent

Author(s): Guldem Mercanoglu*, Goksel Alcın, Yusuf Ozturkmen and Tevfik Cermik

Volume 17, Issue 1, 2024

Published on: 03 November, 2023

Page: [68 - 76] Pages: 9

DOI: 10.2174/0118744710252994231024064842

Price: $65

Abstract

Introduction: Arthritis is an inflammatory disorder that affects one or more joints of the body for various reasons, including autoimmune disorders, trauma, or infection. In many cases, traditional long-term treatment with various drug combinations (NSAIDs, diseasemodifying antirheumatic drugs, systemic corticosteroids, etc.) can provide relief, but many joints require additional local treatment. Radiosynovectomy (RSV) is an alternative method to current treatment options. Both the global supply shortage of 90Y in recent years and the increasing use of 177Lu-labeled radiopharmaceuticals in the field of nuclear medicine have made it possible to develop 177Lu-labeled microparticles and test them in small groups as RSV agents. This study aimed to develop the 177Lu labeled tin colloid formulation and demonstrate its invivo characterization.

Materials and Methods: Particle size, shape, and labelling efficiency of the four formulations developed were determined. The formula with the highest labelling efficiency was selected for further studies. The quality of the formulation was evaluated based on radionuclidic, radiochemical, and microbial purity. In-vitro stability was evaluated by determining the labelling efficiency. In-vitro stability was tested in PBS and synovial fluid. The biological characterization was assessed using SPECT/CT after injecting the formulation into the normal knee joints of the rabbits.

Results: Aggregated colloidal particles were spherical with a particle size of <5 μm. Labelling efficiency and radiochemical purity were >95 and 97.65% (Rf=0.2), respectively. The formulation was stable in vitro for up to 72 hours, both in PBS and synovial fluid. The formulation was homogeneously distributed in the joint at 0 and 1 hour after injection, and radioactivity- related involvement and inguinal lymph node involvement due to possible leakage were not detected in the late period. No pyrogenic/allergic side effects were observed during this period.

Conclusion: 177Lu-tin-colloid was successfully prepared under optimized reaction conditions with high binding efficiency and radiochemical purity. The radiolabeled colloid was found to be stable in-vitro both in PBS and synovial fluid at room temperature. Serial PCET/CT images revealed that the activity was completely retained within the synovial cavity, with no activity leakage out of the joint until 48 hours after the injection. With the support of the results from further clinical studies, it may be possible for the formulation to enter clinical use.

« Previous Next »
Graphical Abstract

[1]
Aletaha, D.; Neogi, T.; Silman, A.J.; Funovits, J.; Felson, D.T.; Bingham, C.O., III; Birnbaum, N.S.; Burmester, G.R.; Bykerk, V.P.; Cohen, M.D.; Combe, B.; Costenbader, K.H.; Dougados, M.; Emery, P.; Ferraccioli, G.; Hazes, J.M.W.; Hobbs, K.; Huizinga, T.W.J.; Kavanaugh, A.; Kay, J.; Kvien, T.K.; Laing, T.; Mease, P.; Ménard, H.A.; Moreland, L.W.; Naden, R.L.; Pincus, T.; Smolen, J.S.; Stanislawska-Biernat, E.; Symmons, D.; Tak, P.P.; Upchurch, K.S.; Vencovský, J.; Wolfe, F.; Hawker, G. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum., 2010, 62(9), 2569-2581.
[http://dx.doi.org/10.1002/art.27584] [PMID: 20872595]
[2]
Taurog, J.D. The spondyloarthritides. In: Harrison’s principles of internal medicine; 17th ed; Fauci, A.S.; Braunwald, E.; Kasper, D.L., Eds., 2110.
[3]
Knut, L. Radiosynovectomy in the therapeutic management of arthritis. World J. Nucl. Med., 2015, 14(1), 10-15.
[http://dx.doi.org/10.4103/1450-1147.150509] [PMID: 25709538]
[4]
Soroa, V.E.; Velázquez Espeche, M.H.; Giannone, C.; Caviglia, H.; Galatros, G.; Fernández, D.; Méndez, M.; Naswetter, G.G.; Nicolini, J.O. Effects of radiosynovectomy with p-32 colloid therapy in hemophilia and rheumatoid arthritis. Cancer Biother. Radiopharm., 2005, 20(3), 344-348.
[http://dx.doi.org/10.1089/cbr.2005.20.344] [PMID: 15989482]
[5]
Bessant, R.; Steuer, A.; Rigby, S.; Gumpel, M. Osmic acid revisited: Factors that predict a favourable response. Rheumatology, 2003, 42(9), 1036-1043.
[http://dx.doi.org/10.1093/rheumatology/keg283] [PMID: 12777647]
[6]
Liepe, K.; Zaknun, J.J.; Padhy, A.; Barrenechea, E.; Soroa, V.; Shrikant, S.; Asavatanabodee, P.; Jeong, M.J.; Dondi, M. Radiosynovectomy using yttrium-90, phosphorus-32 or rhenium-188 radiocolloids versus corticoid instillation for rheumatoid arthritis of the knee. Ann. Nucl. Med., 2011, 25(5), 317-323.
[http://dx.doi.org/10.1007/s12149-011-0467-1] [PMID: 21336817]
[7]
Clunie, G.; Fischer, M. EANM procedure guidelines for radiosynovectomy. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30(3), B12-B16.
[http://dx.doi.org/10.1007/s00259-002-1058-0] [PMID: 12723558]
[8]
Fellinger, K.; Schmid, J. [Local therapy of rheumatic diseases]. Wien. Z. Inn. Med., 1952, 33(9), 351-363.
[PMID: 13006334]
[9]
Gumpel, J.M. 90Y colloids in chronic synovitis of the knee: A review 1970--1977. Rheumatology, 1979, XVIII(Suppl.), 38-41.
[http://dx.doi.org/10.1093/rheumatology/XVIII.suppl.38] [PMID: 441628]
[10]
Topp, J.R.; Cross, E.G.; Fam, A.G. Treatment of persistent knee effusions with intra-articular radioactive gold. Can. Med. Assoc. J., 1975, 112(9), 1085-1089.
[PMID: 1125918]
[11]
Menkes, C.J.; Gô, A.L.; Verrier, P.; Aignan, M.; Delbarre, F. Double-blind study of erbium 169 injection (synoviorthesis) in rheumatoid digital joints. Ann. Rheum. Dis., 1977, 36(3), 254-256.
[http://dx.doi.org/10.1136/ard.36.3.254] [PMID: 327948]
[12]
Kampen, W.U.; Brenner, W.; Czech, N.; Henze, E. Intraarticular application of unsealed beta-emitting radionuclides in the treatment course of inflammatory joint diseases. Curr. Med. Chem., 2002, 1, 77-87.
[13]
Jha, P.; Arora, G.; Shamim, S.A.; Mukherjee, A.; Gautam, D.; Ballal, S.; Kumar, U.; Ansari, T.M.; Bal, C. Lutetium-177 tin colloid radiosynovectomy in patients with inflammatory knee joint conditions intractable to prevailing therapy. Nucl. Med. Commun., 2018, 39(9), 803-808.
[http://dx.doi.org/10.1097/MNM.0000000000000871] [PMID: 29994932]
[14]
Lee, E.B.; Shin, K.C.; Lee, Y.J.; Lee, Y.J.; Cheon, G.J.; Jeong, J.M.; Son, M.W.; Song, Y.W. 188Re-tin-colloid as a new therapeutic agent for rheumatoid arthritis. Nucl. Med. Commun., 2003, 24(6), 689-696.
[http://dx.doi.org/10.1097/00006231-200306000-00012] [PMID: 12766606]
[15]
Shukla, J.; Bandopadhyaya, G.P.; Shamim, S.A.; Kumar, R. Characterization of Re-188–Sn microparticles used for synovitis treatment. Int. J. Pharm., 2007, 338(1-2), 43-47.
[http://dx.doi.org/10.1016/j.ijpharm.2007.01.014] [PMID: 17298870]
[16]
Production, quality control and clinical applications of radiosynovectomy. IAEA radioisotopes and radiopharmaceuticals reports No:3; International Atomic Energy Agency: Vienna, 2021.
[17]
Pillai, M.R.A.; Chakraborty, S.; Das, T.; Venkatesh, M.; Ramamoorthy, N. Production logistics of 177Lu for radionuclide therapy. Appl. Radiat. Isot., 2003, 59(2-3), 109-118.
[http://dx.doi.org/10.1016/S0969-8043(03)00158-1] [PMID: 12941498]
[18]
Das, T.; Pillai, M.R.A. Options to meet the future global demand of radionuclides for radionuclide therapy. Nucl. Med. Biol., 2013, 40(1), 23-32.
[http://dx.doi.org/10.1016/j.nucmedbio.2012.09.007] [PMID: 23116551]
[19]
Shinto, A.; Kamaleshwaran, K.; Chakraborty, S.; Vyshakh, K.; Thirumalaisamy, S.; Karthik, S.; Nagaprabhu, V.; Vimalnath, K.; Das, T.; Banerjee, S. Radiosynovectomy of painful synovitis of knee joints due to rheumatoid arthritis by intra-articular administration of 177 lu-labeled hydroxyapatite particulates: First human study and initial Indian experience. World J. Nucl. Med., 2015, 14(2), 81-88.
[http://dx.doi.org/10.4103/1450-1147.153908] [PMID: 26097417]
[20]
Kossert, K.; Nähle, O.J.; Ott, O.; Dersch, R. Activity determination and nuclear decay data of 177Lu. Appl. Radiat. Isot., 2012, 70(9), 2215-2221.
[http://dx.doi.org/10.1016/j.apradiso.2012.02.104] [PMID: 22429554]
[21]
Pillai, A.M.; Knapp, F.F. Jr Evolving important role of lutetium-177 for therapeutic nuclear medicine. Curr. Radiopharm., 2015, 8(2), 78-85.
[http://dx.doi.org/10.2174/1874471008666150312155959] [PMID: 25771380]
[22]
Arora, G.; Singh, M.; Jha, P.; Tripathy, S.; Bal, C.; Mukherjee, A.; Shamim, S.A. Formulation and characterization of lutetium-177-labeled stannous (tin) colloid for radiosynovectomy. Nucl. Med. Commun., 2017, 38(7), 587-592.
[http://dx.doi.org/10.1097/MNM.0000000000000684] [PMID: 28538080]
[23]
Yousefnia, H.; Jalilian, A.R.; Abbasi-Davani, F.; Zolghadri, S.; Bahrami-Samani, A.; Ghannadi-Maragheh, M. Preparation and quality control of 177Lu-chitosan for radiosynovectomy. Iran. J. Nucl. Med., 2014, 22, 1-6.
[24]
Polyak, A.; Nagy, L.N.; Drotár, E.; Dabasi, G.; Jóba, R.P.; Pöstényi, Z.; Mikolajczak, R.; Bóta, A.; Balogh, L. Lu-177- labeled zirconia particles for radiation synovectomy. Cancer Biother. Radiopharm., 2015, 30(10), 433-438.
[http://dx.doi.org/10.1089/cbr.2015.1881] [PMID: 26683134]
[25]
Chakraborty, S.; Das, T.; Banerjee, S.; Sarma, H.D.; Venkatesh, M. Preparation and preliminary biological evaluation of 177Lu-labelled hydroxyapatite as a promising agent for radiation synovectomy of small joints. Nucl. Med. Commun., 2006, 27(8), 661-668.
[http://dx.doi.org/10.1097/00006231-200608000-00008] [PMID: 16829766]
[26]
Schneider, P.; Farahati, J.; Reiners, C. Radiosynovectomy in rheumatology, orthopedics, and hemophilia. J. Nucl. Med., 2005, 46(Suppl. 1), 48S-54S.
[PMID: 15653651]
[27]
Jeong, J.M.; Lee, Y.J.; Kim, Y.J.; Chang, Y.S.; Lee, D.S.; Chung, J.K.; Song, Y.W.; Lee, M.C. Preparation of rhenium-188–tin colloid as a radiation synovectomy agent and comparison with rhenium-188–sulfur colloid. Appl. Radiat. Isot., 2000, 52(4), 851-855.
[http://dx.doi.org/10.1016/S0969-8043(99)00131-1] [PMID: 10800721]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy